Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Sigyn Therapeutics, Inc. (SIGY) had Return on Tangible Equity of 9.78% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-0.58M |
|
-- |
|
-- |
|
$0.39M |
|
$-0.39M |
|
$-0.19M |
|
$-0.58M |
|
$-0.58M |
|
$-0.58M |
|
$-0.58M |
|
$-0.58M |
|
$-0.58M |
|
$-0.39M |
|
$-0.32M |
|
1.61M |
|
1.61M |
|
$-0.36 |
|
$-0.36 |
|
| Balance Sheet Financials | |
$0.09M |
|
-- |
|
$0.05M |
|
$0.14M |
|
$3.99M |
|
$2.06M |
|
$2.06M |
|
$6.05M |
|
$-5.92M |
|
$-5.92M |
|
$-5.92M |
|
1.60M |
|
| Cash Flow Statement Financials | |
$-0.65M |
|
-- |
|
$0.72M |
|
$0.01M |
|
$0.09M |
|
$0.07M |
|
$0.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-0.54 |
|
-0.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
9.78% |
|
|
Return on Tangible Equity |
9.78% |
-426.72% |
|
15.01% |
|
$-3.69 |
|
$-0.40 |
|
$-0.40 |
|